Deka Biosciences Closes Usd $20 Million Series B2 Financing Led By Mpm Bioimpact

Sep 28, 2023•about 2 years ago

Amount Raised

$20 Million

Round Type

series b

GermantownScience And EngineeringHealth CareBiotechnology

Investors

Detlev BiniszkiewiczAtem Capital And Ceo John MummPlains VenturesAmana InvestmentsAlexandria Venture InvestmentsViva Bio InnovatorO BioLeaps By BayerMpm Bio Impact

Description

Maryland-based biotech company Deka Biosciences ("Deka") today announced that it has successfully closed a USD $20 Million Series B2 financing with a syndicate of life science investors led by MPM BioImpact, and joined by additional investors including Leaps by Bayer, O-Bio (Echo Investment Capital), Viva BioInnovator, Alexandria Venture Investments, Amana Investments, Plains Ventures, ATEM Capital and CEO John Mumm. The proceeds of the financing will support the advancement of Deka's pipeline and drug product manufacturing as they continue clinical trials following the receipt of a notice to proceed letter from the FDA for their investigational new drug (IND) application to evaluate DK210 (EGFR). Additionally, Detlev Biniszkiewicz, Ph.D. of MPM-BioImpact, will join the Deka board.

Company Information

Company

Deka Biosciences, Inc.

Location

20271 GOLDENROD LN SUITE 2087

Germantown, Illinois, United States

About

Deka is an early-stage biotech company focused on the development of novel cytokine therapies to treat cancer and inflammatory diseases such as Crohn's, psoriasis, rheumatoid arthritis and sepsis. The company is led by serial entrepreneur John Mumm, who is backed by a team of experienced biopharma and CDMO innovators with expertise in drug discovery, product development, characterization and testing. Deka has developed disease specific DiakinesTM that maximize patient benefits through improved pharmacokinetics / pharmacodynamics (PK/PD) function via targeted delivery of dual and complimentary cytokines to affected tissues or cells. Through the use of precision medicine, Deka's vision is to maximize the impact of its DiakineTM therapeutic proteins by ensuring treatment of patients who will best benefit from and respond to our cytokine therapies. To learn more, visit www.dekabiosciences.com. SOURCE Deka Biosciences

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends